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Introduction
Currently, there is a lot of discussion about whether generic
substitution of anti-epileptic medicines with the same
active moiety but from different manufacturers can take
place safely. Issues raised in this discussion relate to bio-
equivalence requirements, variability in exposure, prob-
lems with medicine supply, costs of adverse events,
and possible legal consequences when patients do not
provide explicit permission for being switched to a generic
medicine [2–6]. Furthermore, it is not clear what the
consequences are in terms of adverse events, and thus the
costs for society and the consequences for the individual
patient [7].
In most countries, generic substitution is the principal
responsibility of the delivering pharmacist. In a recently
published statement, the American Academy of Neurology
argues that in their opinion the permission of both the
prescribing physician and the patient should be necessary
before generic substitution is allowed to take place
[8]. Analogously, the Netherlands Society of Neurology
and the Dutch League Against Epilepsy state that such
exchange requires careful guidance of and information to
the patient and possibly consultation with the prescribing
physician. Furthermore, they state the importance of con-
tinuity of delivery of the same product (either for generic or
for branded medicines) for this group of patients [9]. It
is understandable that in clinical practice concerns are
expressed related to generic anti-epileptic medicines. After
all, many anti-epileptics are medicines with a narrow
therapeutic index. Besides, the consequences of an epi-
leptic attack are severe, in a physical, psychological and
social respect. Therefore, there is ample ground to look
critically at generic substitution of anti-epileptic medicines.
The Dutch regulatory agency MEB-CBG attaches signiﬁ-
cance to this issue and considers this discussion of the
utmost importance. As a contribution to this discussion,
this position paper considers the conditions with which
generic substitution should comply in order to be safe and
effective.
Generic is exchangeable
When the patent or legal protection period of a medicinal
product has expired, it is possible to apply for marketing a
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DOI 10.1007/s00415-009-5231-2generic version of that medicine. Thus, a situation develops
in which patients are no longer treated with the original
branded medicine (specialite ´, innovator), and generic
substitution occurs. This implies that the branded medicine
is replaced by a medicine with an identical active moiety.
Besides generic substitution, we also recognize therapeutic
substitution. Therapeutic substitution implies that a medi-
cine is replaced by another medicine from the same ther-
apeutic class, e.g., omeprazole by pantoprazole. It is hard
to evaluate this form of substitution as there are hardly any
studies that report on it. This type of therapeutic substitu-
tion will not be covered in this position paper.
A generic is a medicine containing the same active
moiety with the same content and the same pharmaceutical
form as the branded medicine (pharmaceutical equivalent).
If the generic manufacturer can demonstrate that plasma
exposure in time of the generic medicine can be considered
equal to that of a branded medicine (i.e., products are
considered bioequivalent), the generic is considered ther-
apeutically equivalent. In that case the generic applicant
can refer to the investigations presented in the ﬁling for the
branded medicine to support its safety and efﬁcacy. The
assessment of bioequivalence, and thus therapeutic equiv-
alence, of generic medicines and the branded medicine in
the European Community is one of the tasks of the
National Medicines Evaluation Boards and the European
Medicines Agency (EMEA).
A demonstration of equal plasma exposure in time of
two medicines, deﬁned by the area under the plasma con-
centration–time curve (AUC) and the maximum plasma
concentration (Cmax) is called bioequivalence. The under-
lying principle of using bioequivalence to declare thera-
peutic equivalence is that there always ı ´s a relationship
between the plasma concentration–time proﬁle and the
efﬁcacy and toxicity of a medicinal product. This implies
that when the concentration–time proﬁle of the generic
active moiety is equal to that of the branded medicine, the
efﬁcacy and safety as far as the active moiety is concerned
will be the same as well.
In principle, a bioequivalence study is a study with a
two-way cross-over design, mostly conducted in healthy
volunteers. The volunteers receive the generic and the
branded medicines in a randomised sequence, with an
appropriate washout period in between. Before and after
drug intake, plasma concentrations are determined at reg-
ular timepoints. Essential to these studies is that the same
active moiety derived from two different formulations (i.e.,
generic and branded) are compared for the same individual.
The individual thus becomes his/her own control. The
comparison of the pharmacokinetics of the active moiety
should be in strict accordance with European requirements
with regard to AUC and Cmax [10], which are determined
in these studies as a measure for the extent and rate of
absorption. The requirements posed in Europe related to
bioequivalence are comparable to those in other western
countries, such as the USA and Canada. In all cases, the
AUC and Cmax for the generic and branded medicine
should equal; more speciﬁcally, the 90% conﬁdence
interval of the ratio AUCgeneric/AUCbranded and Cmax-generic/
Cmax-branded should be between 0.80 and 1.25. These limits
are based on clinical relevance of potential differences in
exposure and are accepted as such internationally [10, 11].
Other issues regarding further regulatory points of attention
in the assessment of bioequivalence are that the study is
sufﬁciently powered, that an adequate and validated ana-
lytical method is applied, and GCP/GLP conditions are
implemented.
The bioequivalence study will reveal whether ‘inactive’
excipients of a medicinal product play a role in the
absorption of the active moiety. If this is the case, con-
centration–time proﬁles will differ, and when 90% conﬁ-
dence intervals do not comply with the requirements,
registration of the generic medicine is not possible.
Supplementary requirements for bioequivalence studies
apply in cases of special formulations, such as products
with controlled release. For instance, minimal plasma
concentrations (Cmin), peak-trough ﬂuctuations and a pos-
sible food interaction will be included in the assessment.
Furthermore, dose-dumping, i.e., the immediate release of
the full dose, should be excluded in vivo [11].
Anti-epileptic generics in the EU
Generic formulations are currently available for a number
of anti-epileptics. An overview of registered anti-epileptics
in the EU is provided in Table 1.
For a number of formulations, such as carbamazepine
and valproic acid, different pharmaceutical formulations
are marketed. Carbamazepine, for example, is available as
an immediate release (IR) and a controlled release (CR)
tablet, and valproic acid as an IR, a CR and an enteric
coated (EC) formulation. Generics are registered separately
for all these formulations, and all these individual generics
fulﬁll the requirements as stated earlier. Since the phar-
macokinetics of the active moiety, and thus the efﬁcacy
and safety, is inﬂuenced by the type of formulation, it is
obvious that an IR formulation in principle cannot be
exchanged with a CR or EC formulation, nor an EC with an
IR or CR formulation. However, substitution to an equiv-
alent formulation of the same active moiety, e.g., substi-
tution from Tegretol
 to the carbamazepine IR generic, and
from Tegretol CR to the CR generic will result in equal
exposure in time and therapeutic equivalence.
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A frequently expressed worry is that bioequivalence studies
are conducted in healthy volunteers rather than in the
actual target patient population [5]. However, no data have
been published as yet that indicate that relative differences
in bioavailability of generic and branded medicines in
healthy volunteers would translate to other relative values
in the patient population.
This can be understood by considering the basis of
generic applications, i.e., the fact that when absorption of
the active moiety from the branded and generic medicine
is equal (i.e., bioequivalent), further effects in actual
patients, in patients with renal or hepatic impairment, in the
young and the elderly will be equal as well. In all cases, it
is the effects after proven equal absorption which deter-
mine this effect, and after absorption of the active moiety
in the circulation there is no plausible difference between
the active moiety originating from the branded or generic
medicine (‘the active moiety does not know its origin’).
The fact that individual patients may obtain different
plasma levels due to differences in metabolism of excretion
does not impair this conclusion, because this will be the
case both for the branded and the generic medicine to
the same extent. The generic and the branded medicine
thus remain therapeutically equivalent.
Bioequivalence criteria are sometimes explained as the
possibility ‘that there could be as much as a 56% increase
or a 36% decrease in bioavailability when switching
between different generic formulations’ [4]. If so, this
expectedly would pose a problem, especially for narrow
therapeutic drugs. However, using the statistical criteria
(90% conﬁdence interval within 0.80–1.25), it is difﬁcult
for any generic product whose mean arithmetic bioavail-
ability parameters differ by more than 10% from the ref-
erence to meet the conﬁdence interval requirements, and it
is virtually impossible to meet the conﬁdence interval
requirements if these differences approach 20%. Further-
more, an FDA review demonstrated that the average dif-
ference between the bioequivalence of more than 270
generic medicines approved in 1997 and their trade-name
counterparts was 3.5% [12]. Although not formally inves-
tigated, ﬁgures in the European Union will not be too much
different from these ﬁgures reported by the FDA. Also the
Table 1 Branded and generic
oral anti epileptic medicines
available on the EU market
IR immediate release, CR
controlled release, EC enteric
coated (gastroresistant)
a In some countries no branded
medicine on the market
Active moiety Branded Formulation Generic
registered
Carbamazepine Tegretol IR, tablet, suspension Yes
Tegretol CR CR, tablet Yes
Clobazam Frisium IR, tablet No
Clonazepam Rivotril IR, tablet No
Diazepam Stesolid, Valium a.o. IR, tablet Yes
Ethosuximide Ethymal EC, capsule, No
IR, suspension
Felbamate Taloxa IR, tablet, suspension No
Gabapentin Neurontin IR, capsule, tablet Yes
Pregabalin Lyrica IR, capsule No
Lamotrigine Lamictal IR, capsule, tablet, dispersible
tablet
Yes
Levetiracetam Keppra IR, tablet, oral solution No
Nitrazepam Mogadon, Apodorm, Insomin,
Remnos, a.o.
IR, tablet Yes
Oxcarbazepine Trileptal IR, tablet, suspension Yes
Phenobarbital Luminal, Phenobarbital IR, tablet Yes
a
Phenytoin Diphantoine IR, tablet No
Primidone Mysoline IR, tablet No
Topiramate Epitomax, Topamax, Topaz-25 IR, tablet, capsule Yes
Valproic acid Convulex, Depacon, Depakene,
Depakine, Depakote,
Divalproex, Epiject, Epilim,
Epival, Orlept a.o.
IR, tablet Yes
CR, tablet
CR, granulate
EC, capsule
Vigabatrin Sabril IR, tablet, granulate No
Zonisamide Zonegran IR, capsule No
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dence interval may be fuelling concerns. However, despite
thisarbitrarydecision,thelong-termexperiencewithgenerics
world-wide shows that this margin is adequate in a vast
majority of the cases to govern effective and safe substitution
ofgenericformulations.Hypersensitivitytocertainexcipients
may occur [7], but is limited to exceptional cases.
Generic–generic substitution also deserves attention.
Generics are evaluated by comparison with the branded
product. One could argue that generic–generic substitution,
which is likely to occur in practice, is not investigated, and
may be more prone to bioinequivalent exposure. Based on
the average difference in exposure between the branded
product and the generic of 3.5% [12] this is a rather remote
possibility. The original publication on generic–generic
substitution by Anderson et al. [13] indicated that while
driftingispossible,intheory,whenexchangingtwogenerics
with opposite point estimates (e.g., one being \0.90, one
being [1.10), these occasions are very rare. Currently,
investigations are ongoing within the Dutch Medicines
Agency investigating this possibility by comparing the
exposure of different generic antiepileptic drugs (i.e., topi-
ramate and gabapentin) obtained from all actually ﬁled
bioequivalence studies that led to approval, and estimating
the 90% conﬁdence intervals for such substitution. Mean
ratios for topiramate AUC and Cmax from nine ﬁled
bioequivalence studies were 1.014 ± 0.014 and 1.000 ±
0.042,respectively.Forgabapentin(800 mg),themeanratio
for AUC obtained in three studies was 0.988 ± 0.018, and
0.988 ± 0.25 for Cmax. Preliminary results of this investi-
gation into generic–generic substitution indicate that in
almost all cases the 90% conﬁdence intervals obey the 80–
125 margin (Personal communication).
Unfamiliarity with generic medicines, and thus less faith
in them, is a well-known phenomenon. This phenomenon,
potentially fuelled by possible differences in shape or color
between the generic and branded medicine, may initiate
doubts in prescribing physicians and patients. When, on top
of this, patients are being provided successively with
generic medicines from various origins, be it due to a
change in purchase policy of the pharmacist or the health
insurance company, doubts can be ampliﬁed with negative
effects on compliance. In our opinion, this aspect certainly
deserves the attention of the delivering pharmacist.
The issue of generic antiepileptics is rather old, since a
number of generic antiepileptics, e.g., carbamazepine and
valproic acid, have been marketed for a long time.
Carbamazepine was indeed one of the ﬁrst generic anti-
epileptics about which worries were expressed [14].
Because of the concerns at that time, further pharmacoki-
netic and clinical investigations were conducted on behalf
of the Dutch Regulatory Agency, in which the ‘older’
carbamazepine generic medicines were compared with the
branded Tegretol [15, 16]. Results from these investiga-
tions demonstrated that pharmacokinetics of carbamaze-
pine and its metabolites were not clinically signiﬁcantly
different for Tegretol and its generics. Moreover, no dif-
ference in subjective complaints and cognitive functions
was noted between patients using any of these medicines.
Until April 1st, 2008, the Netherlands Pharmacovigilance
Centre Lareb (Lareb) has received 2,103 reports mentioning
an antiepileptic agent as the suspected drug. In 26 of these
reported cases, a possible relationship was indicated between
substitution from a branded medicine to a generic one. It is
reassuringthatarelativelylownumberofreportswasreceived
by Lareb over all these years that indicate problems due to
switchingfrombrandedantiepileptic drugs togeneric ones. It
shouldberequiredtoreportalcasesofADRspossiblyrelated
to substitution to the national pharmacovigilance centers.
Only then can the prescribing physician, pharmacist and
patient contribute to an optimal surveillance of generic med-
icines,andprovidetheopportunitytopickupsignalsthatmay
p o i n tt op r o b l e m si nc l i n i c a lp r a c t i c e .
Most literature data on issues regarding switching of
antiepileptic medicines is based on surveys. One survey,
conducted in Germany, Austria and Switzerland, indicated
that 50% of the responding treating neurologists had
experienced at least one problem possibly related to sub-
stitution of a generic medicine. The relation with an epi-
leptic attack was not mentioned in this study [17]. Also the
frequency of switching back from a generic to a branded
antiepileptic medicine has been a subject of investigation
[18]. Besides the actual ﬁndings, results from these studies
appear to indicate that the level of acceptance of a generic
medicine by the patient, physician and pharmacist plays a
vital role in switching. Only in rare occasions was a rele-
vant reduced exposure reported upon switching to a generic
antiepileptic drug [5]. Other articles have published results
of surveys on problems related to switching to generics
[17, 19–21]. However, although these surveys undoubtedly
express the opinions of many people involved in generic
substitution, these surveys do not provide evidence for real
differences and a causal relationship between generic
substitution and, for example, the occurrence of seizures.
We are of the opinion that survey-type investigations do
not provide a good reﬂection of the reality of a problem.
Additional studies should be conducted to establish any
differences between brand and generic products. Recently,
a case-control study by Zachry et al. [22] indicated that
epilepsy patients with an epilepsy event requiring hospi-
talization, emergency room visit, or ambulance had 81%
higher odds of having had a switch to a generic than
patients with an epilepsy event requiring an ofﬁce visit. Of
note, most (approximately 40%) of the patients in this
study were switched to a zonisamide generic, which is not
available yet in the EU. Although this case-control study is
J Neurol (2009) 256:1966–1971 1969
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follow-up investigations. For such studies, in order to
evaluate the impact of the general acceptance level on the
judgment of the effect, a randomised and especially blin-
ded setup is required. In this respect the initiative of the
American Epilepsy Society to try and initiate such a blin-
ded prospective trial is highly welcomed [23, 24].
Other causes for the occurrence of seizures during
antiepileptic treatment
Increased susceptibility to seizures may be due to pharma-
cokinetic interactions with new comedications or comedica-
tion that has been withdrawn. E.g., carbamazepine is
metabolized by cytochrome P450 3A4 [25], valproic acid
by UDP-glucuronosyltransferase (UGT) 2B7 [26], and phe-
nytoin by cytochrome P450 2C9 [27]. Consequently, the
inhibition or induction of these metabolizing agents by
comedication is prone to affect the clinical outcome for these
antiepileptic medicines. Moreover, many of the antiepileptic
medicines have an enzyme inducing effect, which compli-
catespredictionofthesekindofpharmacokineticinteractions
in clinical practice, in particular when more antiepileptic
drugsare beingcombined,asreviewedbyPatsalosetal.[28].
Thecomplexityofsuchinteractionsisfurtherillustrated,e.g.,
by lamotrigine, which is known to interact with the estrogen
componentofcontraceptiveagents,aninteractionthatappears
period-dependent[29,30].Moreover,thesepharmacokinetics
are also strongly inﬂuenced by pregnancy [31–33], a phe-
nomenon also described for levetiracetam [34].
Besides these pharmacological issues, compliance may
also be critical in the occurrence of seizures during anti-
epileptic treatment. Compliance of epilepsy patients in the
course of time has been reported to change, sometimes as a
consequence of receiving a generic that is not trusted [35].
In this respect it may be desirable not to enforce a frequent
switch between different generic brands, in order to limit
possible worries of the patient as much as possible.
Handoko et al. [36] indicated that patients who started,
besides their normal anti-epileptic medication, several
non-antiepileptic comedications, experienced a 5-times
increased chance of an epilepsy-related hospitalization.
Although at this moment a causal relationship still needs to
be conﬁrmed, it is an illustration of the complexity of the
issue. In our opinion, a causal pharmacological relationship
between switching to or between antiepileptic generic
medicines and the occurrence of seizures is not very likely.
Summary
Bioequivalence requirements are very strict and are the
basis of therapeutic equivalence between innovators and
generics. Therefore, switching to a generic anti-epileptic
medicine appears to be safe based on pharmacokinetic
grounds, and does not appear to provide a plausible phar-
macological explanation for those cases where seizure
frequency or seizure patterns change during antiepileptic
treatment. Other causes may contribute, such as pharma-
cokinetic or pharmacodynamic drug–drug interactions.
Another important factor may be lack of compliance,
due to poor acceptance of a generic medicine. Frequent
switching to other generics could negatively inﬂuence
compliance and should be avoided.
There is a major discrepancy between the actual number
of reported adverse events upon switching and the opinion
on this subject in clinical practice. It is crucial that both
prescribers and pharmacists report adverse events, in order
to allow them to take appropriate action when necessary.
By doing so, prescribing physician, pharmacist and patient
can contribute to an optimal surveillance of generic
medicines, and thus contribute to the wellbeing of the
patients at stake.
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